Ceftolozane/tazobactam (C/T) could be an effective treatment for some patients with severe extended-spectrum β-lactamase-producing Enterobacterales
(ESBL-E) infections, according to a recent study in Italy.
The multicenter, retrospective study, published in Open Forum Infectious Diseases
, reviewed C/T treatment in 153 patients whose diagnoses included hospital-acquired pneumonia (n = 46 [30%]) and complicated urinary tract infections (n = 34 [22.2%]). Favorable clinical outcomes—resolution of symptoms and lack of microbiological evidence of infection—were observed in 128 (83.7%) patients.
“This study reports the largest clinical experience with C/T therapy for the treatment of serious ESBL-E infection, published so far,” the study noted. “We showed that C/T is an effective drug for treating different types of ESBL-E infections.”
The study, funded by a research grant from Merck & Co., showed an increased risk of failure among patients with a higher Charlson comorbidity index, presentation of septic shock and continuous renal replacement therapy (CRRT). Sepsis was reported in 38.6% of patients, and septic shock in 27.5% of patients.
“Clinicians should be aware of the risk of clinical failure with C/T therapy in septic patients receiving CRRT,” the study noted.
The study involved patients treated at 12 centers with a median age of 69. Along with pneumonia and UTIs, diagnoses in the study included acute bacterial skin and skin-structure infections, complicated intra-abdominal infections and concomitant bloodstream infection. Pathogens included Escherichia coli
in 48.3% of cases, Klebsiella pneumoniae
in 29.4% and and Enterobacter
spp in 14.4%.
C/T was administered for a median duration of 14 days as monotherapy in 83% of patients and in combination in 17% with no statistically significant difference in outcomes between mono and combo treatments. Successful clinical outcomes were reported in 128 patients, including 100% of patients treated with empiric therapy, 83.8% of targeted therapy and 66.7% of rescue therapy.
Clinical failure was reported in 25 patients, including lack of clinical response in 4, recurrence of infection in 6, and mortality in 15. Resistance to C/T developed during therapy in 3 patients.
Limitation of the study included that it was a retrospective study unable to control for variables; C/T was administered as a second- or third-line therapy and it is unclear how prior therapies may have affected outcomes; molecular analysis of antibiotic resistance was unavailable; and antibiotic blood levels weren’t performed.
Carbapenems are a first choice for treatment of ESBL-E infections, which are associated with high rates of treatment failure and mortality. But an increase in carbapenem-resistant Enterobacterales
strains has sparked a move toward other treatments. This study is in line with previous studies, including the recently published paper ASPECT-NP.
Hospitals have made progress in efforts to reduce multi-drug resistant infections, but ESBL infections remain a growing challenge. A recent study found decreases in 4 of 6 pathogens at 890 U.S. hospitals from 2012 through 2017, but the incidence of carbapenem-resistant Enterobacteriaceae remained steady and ESBL infections increased
by 53.3% during that time.
Preventing ESBL-E infections has been an area of focus. A recent study examined contact isolation precautions
at 20 hospitals in Germany, the Netherlands, Spain, and Switzerland and found that in non-critical care units contact isolation revealed no benefits when used in addition to standard precautions.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.